期刊文献+

40例骨髓增生异常综合征染色体核型及凋亡 被引量:1

Karyotype and apoptosis of 40 cases with myelodysplastic syndrome
原文传递
导出
摘要 目的探讨不同类型骨髓增生异常综合征(MDS)患者骨髓染色体核型和凋亡现象及其机制。方法采用骨髓短期培养和G显带技术对40例MDS患者进行染色体核型分析,钙磷脂结合蛋白(Annexin-Ⅴ)-FITC标记药物骨髓单个核细胞,了解其早期凋亡的情况,逆转录-PCR分析自杀相关因子(Fas)和凋亡抑制蛋白(survivin,生存素)mRNA表达变化。结果 20/40例MDS患者检出染色体异常,其中难治性贫血(RA)7/20例(35%),RA伴有环状铁幼粒细胞(RARS)1/2例(50%),RA伴多系发育异常(RCMD)5/8例(62.5%),RA伴原始细胞增多(RAEB)7/10例(70%);国际预后评分系统(IPSS)1年白血病转化率为低危组5%(1/20),中危1、2组25%(3/12),高危组75%(6/8),各组间差异有统计学意义(P<0.05);骨髓单个核细胞凋亡MDS患者高于10例正常体检者(对照组),从低危组到高危组凋亡减少,生存素基因mRNA表达增加,FasmRNA表达下降。结论染色体核型分析在MDS的预后评估中有重要价值;MDS从低危组到高危组凋亡减少,可能与生存素、Fas基因表达有关。 Objective To explore the karyotype and apoptosis of 40 cases with myelodysplastic syndrome(MDS).Methods Chromosome analysis was performed in 40 cases of MDS using the short-term culture of bone marrow cell and G-banding technique. Apoptosis was observed by Annexin Ⅴ-FITC.The mRNA expressions of factor associated suicide(Fas) and survivin were detected by reverse transcription-PCR.Results Karyotype analysis showed that 20 cases(50%) had clonal karyotypic abnormalities.The rate of abnormal karyotype in refactory anemia(RA) was 35%(7/20),while 50%(1/2) in refractory anemia with ring sideroblasts(RARS),62.5%(5/8) in refractory cytopenia with multilineage dysplasia(RCMD) and 70%(7/10) in refractory anemia with excess blasts (RAEB).The rate of transformation to leukemia in high risk patients was 75%(6/18) in 1 year.One case(1/20) in low risk had transformed into leukemia,and 3(3/12) in groups of middle risk 1 and middle risk 2.Apoptosis of MDS patients was severer than that of control group.In MDS patients going from low-risk to high-risk,the apoptosis decreased and mRNA expression of survivin increased,but Fas decreased.Conclusion Karyotype is of importance in evaluating the prognosis of MDS.In MDS patients going from low-risk to high-risk,the apoptosis is decreased,which may be related to Fas and survivin expression.
出处 《江苏医药》 CAS CSCD 北大核心 2010年第10期1135-1137,共3页 Jiangsu Medical Journal
关键词 骨髓增生异常综合征 凋亡 生存素 自杀相关因子 Myelodysplastic syndrome Apoptosis Survivin Factor associated suicide(Fas)
  • 相关文献

参考文献5

二级参考文献29

  • 1Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量:214
  • 2邵宗鸿.骨髓增生异常综合征的发病机制[J].中华血液学杂志,2004,25(11):701-702. 被引量:22
  • 3燕翔,丁强,张元芳,孙则禹,徐永华.尿路上皮癌Survivin的表达及其临床意义[J].临床肿瘤学杂志,2006,11(5):351-354. 被引量:5
  • 4杨崇礼 张之南 主编.骨髓增生异常综合征[A].张之南,主编.血液病诊断和疗效标准:第2版[C].北京: 科学出版社,1998.258~267.
  • 5Schmetzer HM, Poleck B, Duell T, et al. Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes. Ann Hematol, 2000,79: 20-29.
  • 6Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newlydiagnosed chronic myeloid leukemia. N Engl J Med, 2003,349:1423-1432.
  • 7Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 2000,96: 9671-9674.
  • 8Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic signification of chromosomal abnormalities in 640 patients with primary myelodysplastic syndrome. Br J Haematol, 2000, 108:346-356.
  • 9Jotterand M, Parlier V. Diagnosis and pronostic signification of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma, 1996,23:253-266.
  • 10Jaffe ES, Harris NL, Stein H, et al. eds. Pathology and genetics of tumours of heamatopoietic and lymphoid tissues. World Health Organization Classification of Tumours 3. Lyon, France: IARC Press,2001. 61-73.

共引文献50

同被引文献18

  • 1Pang WW,Pluvinage JV,Price EA,et al.Hematopoietic stem cell andprogenitor cell mechanisms in myelodysplas- tic syndromes[J].Proc Natl Acad Sci USA,2013,110(8):3011-3016.
  • 2Tefferi A,Vardiman JW.Myelodysplastic syndromes[J].N Engl J Med,2009,361(19):1872-1885.
  • 3Orazi A,Germing U.The myelodysplastic/myeloprolifera- tive neoplasms:myeloproliferative diseases with dysplas- tic features[J].Leukemia,2008,22(7):1308-1319.
  • 4Plilhom H,Herrmann M,Harms H,et al.Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome[J]. Histopathology,2012,61(2):200-211.
  • 5Zoi K,Cross NC.Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable[J].Int J Hematol, 2015,101(3):229-342.
  • 6Valent P,Horny HP,Bennett JM,et al.Definitions and stan- dards in the diagnosis and treatment of the myelodysplas- tic syndromes:consensus statements and report from a working conference[J],Leuk Res,2007,31(6):727-736.
  • 7Brunning RD,Orazi A,Germing U,et al.Myelodysplastic syndroms/neoplasms,overview[C]// Swerdlow SH,Campo E,Harris NL,et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.Edited by(IARC, Lyon),2008:88-93.
  • 8Greenberg PL,Tuechler H,Schanz J,et al.Revised inter- national prognostic scoring system for myelodysplastic syn- dromes[J].Blood,2012,120(12):2454-2465.
  • 9Piazza GA,Rahm AL,Krutzsch M,et al.Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis[J].Cancer Res,1995,55(14):3110-3116.
  • 10Greenberg PL.Molecular and genetic features of myelodys- plasticsyndromes[J].Int J Lab Hematol,2012,34(3):215-222.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部